Study identifier:7054IT/0003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A comparative trial of the efficacy of two different Nolvadex (NDX) dosing and scheduling regimens in preventing gynecomastia induced by Casodex (CDX) 150 monotherapy in prostate cancer patients. An open, multicenter, phase III trial.
prostate cancer
Phase 3
No
Bicalutamide, Tamoxifen
Male
180
Interventional
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The aim of the study is to investigate the efficacy of different dosing and scheduling of Nolvadex in preventing gynecomastia/mastalgia induced by Casodex 150 mg monotherapy in patients with prostate cancer.
Location
Location
Bari, BA, Italy
Location
Bologna, BO, Italy
Location
Como, Italy
Location
Catania, CT, Italy
Location
Bagno a Ripoli, FI, Italy
Location
FIRENZE, FI, Italy
Location
Genova, GE, Italy
Location
Pisa, PI, Italy
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.